Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Biogen Idec
(NQ:
BIIB
)
201.18
+15.82 (+8.53%)
Streaming Delayed Price
Updated: 4:00 PM EST, Feb 6, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
3,404,877
Open
187.01
Bid (Size)
190.00 (100)
Ask (Size)
200.18 (200)
Prev. Close
185.36
Today's Range
184.60 - 202.41
52wk Range
110.03 - 202.41
Shares Outstanding
146,800,000
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Why Biogen Stock Surged Almost 9% Higher on Friday
↗
February 06, 2026
It's obvious that the company has a good shot at returning to growth.
Via
The Motley Fool
What's going on in today's session: S&P500 movers
↗
February 06, 2026
Via
Chartmill
Performance
YTD
+13.1%
+13.1%
1 Month
+7.6%
+7.6%
3 Month
+29.4%
+29.4%
6 Month
+54.0%
+54.0%
1 Year
+41.3%
+41.3%
More News
Read More
Biogen (BIIB) Q4 Earnings Preview: The "New Biogen" Emerges as Alzheimer's and Rare Disease Pipelines Take Center Stage
February 06, 2026
Via
MarketMinute
Topics
Intellectual Property
Biogen (BIIB) Q4 2025 Earnings Call Transcript
↗
February 06, 2026
Via
The Motley Fool
Topics
Earnings
Biogen (BIIB) Deep Dive: Navigating the Pivot from MS Giant to Neuro-Innovation Powerhouse
February 06, 2026
Via
Finterra
Topics
Earnings
Economy
Intellectual Property
Biogen’s (NASDAQ:BIIB) Q4 CY2025: Strong Sales
February 06, 2026
Via
StockStory
Topics
Artificial Intelligence
Biogen (BIIB) Reports Q4: Everything You Need To Know Ahead Of Earnings
February 04, 2026
Via
StockStory
Topics
Artificial Intelligence
World Trade
Stay updated with the S&P500 stocks that are on the move in today's pre-market session.
↗
February 04, 2026
Via
Chartmill
Nature Medicine Publishes Results from the Pivotal DEVOTE Study of High-Dose Regimen of Nusinersen in Spinal Muscular Atrophy
February 04, 2026
From
Biogen Inc.
Via
GlobeNewswire
1 Cash-Producing Stock to Keep an Eye On and 2 We Find Risky
February 02, 2026
Via
StockStory
Biogen’s Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus, a Disease With No Targeted Treatment Options
January 28, 2026
From
Biogen Inc.
Via
GlobeNewswire
3 Biotech Stocks That Look Like “Sure-Fire” Winners in 2026
↗
January 20, 2026
Via
MarketBeat
Which S&P500 stocks are gapping on Wednesday?
↗
January 14, 2026
Via
Chartmill
Biogen Receives European Commission Approval for High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy
January 12, 2026
From
Biogen Inc.
Via
GlobeNewswire
3 Reasons to Sell BIIB and 1 Stock to Buy Instead
January 11, 2026
Via
StockStory
The Trillion-Dollar Pharmacist: A 2026 Deep Dive into Eli Lilly (LLY)
January 09, 2026
Via
PredictStreet
Topics
Earnings
Economy
Intellectual Property
The Great Decoupling: How the AI Monetization Era Reshaped the Nasdaq in 2025
December 26, 2025
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Stocks
Biogen Inc. (NASDAQ:BIIB) Shows Strong Technical Setup for Potential Breakout
↗
December 26, 2025
Via
Chartmill
The Trillion-Dollar Pharma: A Deep Dive into Eli Lilly’s (LLY) Dominance in the Weight-Loss Era
December 25, 2025
Via
PredictStreet
Topics
Economy
Government
Intellectual Property
The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS
December 22, 2025
From
Biogen Inc.
Via
GlobeNewswire
Therapeutics Stocks Q3 In Review: Biogen (NASDAQ:BIIB) Vs Peers
December 21, 2025
Via
StockStory
Topics
Artificial Intelligence
Biogen (BIIB) Stock Trades Up, Here Is Why
December 19, 2025
Via
StockStory
Topics
Artificial Intelligence
Economy
$7 Trillion "Witching Hour": Unprecedented Derivatives Expiration Sparks Volatility on Wall Street
December 19, 2025
Via
MarketMinute
Topics
Derivatives
Economy
Regulatory Compliance
1 Nasdaq 100 Stock Worth Your Attention and 2 Facing Headwinds
December 18, 2025
Via
StockStory
3 Healthcare Stocks We Think Twice About
December 10, 2025
Via
StockStory
Topics
Stocks
Frequently Asked Questions
Is Biogen Idec publicly traded?
Yes, Biogen Idec is publicly traded.
What exchange does Biogen Idec trade on?
Biogen Idec trades on the Nasdaq Stock Market
What is the ticker symbol for Biogen Idec?
The ticker symbol for Biogen Idec is BIIB on the Nasdaq Stock Market
What is the current price of Biogen Idec?
The current price of Biogen Idec is 201.18
When was Biogen Idec last traded?
The last trade of Biogen Idec was at 02/06/26 04:00 PM ET
What is the market capitalization of Biogen Idec?
The market capitalization of Biogen Idec is 29.53B
How many shares of Biogen Idec are outstanding?
Biogen Idec has 30B shares outstanding.
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.